Signal from the log
Bios Life
25 M$ · Early stage · United States · Health software
Société de Boston fondée par d'anciens dirigeants de BioNTech, qui construit une surveillance du cancer par intelligence artificielle pour les personnes à haut risque et les survivants. Elle personnalise le dépistage puis assure le suivi par télémédecine, en partenariat avec Tempus. Elle vise les quarante millions d'Américains concernés, dont le suivi est aujourd'hui fragmenté et réactif.
Verified
Announced on , logged by the watch of 10 August 2026.
- Operation
- Funding round
- Announced amount
- 25 M$
- Stage
- Early stage
- Country
- United States
- Sector
- Health software
What the log says
Editorial note, in French
Communiqué ouvert, montant relu et fonds nommés.
The investors
Led by Redmile , Vsquared Ventures , Kindred Capital
Provenance
Source endpoints
Logged on 10 August 2026
Description Written in French during the watch run. Written during the watch run, after reading the issuer's press release or the source article.
Verification Amounts and fund names were double checked against the issuer's press release or an official filing.
What this status means
Verified The press release was opened: amount double checked, funds named. The article remains to be written.
The rule A signal is never removed from the log. A round set aside stays readable with its reason, because a collection you cannot reread is a collection you cannot correct.